JP2020534354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534354A5 JP2020534354A5 JP2020536930A JP2020536930A JP2020534354A5 JP 2020534354 A5 JP2020534354 A5 JP 2020534354A5 JP 2020536930 A JP2020536930 A JP 2020536930A JP 2020536930 A JP2020536930 A JP 2020536930A JP 2020534354 A5 JP2020534354 A5 JP 2020534354A5
- Authority
- JP
- Japan
- Prior art keywords
- cdk19
- tnbc
- treatment
- seq
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 14
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims 13
- 101710179322 Cyclin-dependent kinase 19 Proteins 0.000 claims 13
- 230000000295 complement effect Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 5
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 210000000069 breast epithelial cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560140P | 2017-09-18 | 2017-09-18 | |
| US62/560,140 | 2017-09-18 | ||
| PCT/US2018/051489 WO2019055977A1 (en) | 2017-09-18 | 2018-09-18 | METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534354A JP2020534354A (ja) | 2020-11-26 |
| JP2020534354A5 true JP2020534354A5 (enExample) | 2021-10-28 |
| JP7392954B2 JP7392954B2 (ja) | 2023-12-06 |
Family
ID=65723126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536930A Active JP7392954B2 (ja) | 2017-09-18 | 2018-09-18 | トリプルネガティブ乳癌の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11471477B2 (enExample) |
| EP (1) | EP3684420A4 (enExample) |
| JP (1) | JP7392954B2 (enExample) |
| CN (1) | CN111278469A (enExample) |
| AU (1) | AU2018333072B2 (enExample) |
| CA (1) | CA3075784A1 (enExample) |
| WO (1) | WO2019055977A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240390386A1 (en) * | 2021-09-16 | 2024-11-28 | University Of South Carolina | Cdk8/19 inhibitors for preventing drug resistance |
| CN114908168A (zh) * | 2022-05-04 | 2022-08-16 | 重庆大学附属肿瘤医院 | 一种mon1a表达水平检测试剂在制备卵巢癌干性诊断试剂中的应用 |
| CN114854755B (zh) * | 2022-05-30 | 2023-05-23 | 陕西师范大学 | 一种抑制vstm2l表达的慢病毒载体及其应用 |
| CN114832110B (zh) * | 2022-06-21 | 2023-04-28 | 中山大学孙逸仙纪念医院 | 长链非编码rna crcal-3抑制剂在制备治疗放疗抵抗乳腺癌的产品中的用途 |
| CN120693413A (zh) * | 2022-11-07 | 2025-09-23 | Cbs生物科学有限公司 | 预测和治疗三阴性乳腺癌的方法和复合物 |
| EP4620979A1 (en) * | 2022-11-14 | 2025-09-24 | Cognano, Inc. | Antibody and method for producing antibody |
| WO2025020931A1 (en) * | 2023-07-21 | 2025-01-30 | The Chinese University Of Hong Kong | Cdk20 in cancer diagnosis and therapy |
| CN116773815B (zh) * | 2023-08-14 | 2023-11-10 | 四川省医学科学院·四川省人民医院 | Slc2a6作为治疗靶点和筛查靶点的用途及乳腺癌筛查试剂盒 |
| CN117144008B (zh) * | 2023-08-31 | 2024-03-08 | 武汉科技大学 | 三阴性乳腺癌生物标志物及其应用 |
| CN118001402B (zh) * | 2024-01-10 | 2025-09-05 | 中山大学 | Pacsin2在促进sting信号通路激活中的应用 |
| CN119264251B (zh) * | 2024-12-09 | 2025-03-14 | 上海交通大学医学院附属仁济医院 | 一种cbln1单克隆抗体和应用 |
| CN120309727B (zh) * | 2025-06-13 | 2025-08-15 | 昆明医科大学 | 一种靶向人igfl1的单域抗体及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US20080293142A1 (en) | 2007-04-19 | 2008-11-27 | The Board Of Regents For Oklahoma State University | Multiple shRNA Expression Vectors and Methods of Construction |
| ES2927225T3 (es) | 2009-04-17 | 2022-11-03 | Univ Oxford Innovation Ltd | Composición para entrega de material genético |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| CN104220066A (zh) * | 2010-11-19 | 2014-12-17 | 皮拉马尔企业有限公司 | 紫杉醇和cdk抑制剂药物组合物 |
| GEP201706771B (en) * | 2011-09-13 | 2017-11-27 | TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY | |
| MY167390A (en) | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| GB201121069D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
| EP3431087A1 (en) | 2012-02-02 | 2019-01-23 | Senex Biotechnology, Inc. | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer |
| WO2014071143A1 (en) | 2012-11-01 | 2014-05-08 | University Of South Carolina | Method for treating prostate cancer |
| WO2015002956A1 (en) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| US20170115308A1 (en) | 2014-11-14 | 2017-04-27 | Senex Biotechnology, Inc. | Assay to measure efficacy of cdk8/19 inhibitors |
| UY36363A (es) * | 2015-01-19 | 2016-04-01 | Takeda Pharmaceutical | Compuesto heterocíclico fusionado |
| TW201714883A (zh) * | 2015-10-16 | 2017-05-01 | 武田藥品工業股份有限公司 | 雜環化合物 |
| WO2018139660A1 (ja) | 2017-01-30 | 2018-08-02 | 国立大学法人京都大学 | 新規化合物及び制御性ｔ細胞の製造方法 |
-
2018
- 2018-09-18 JP JP2020536930A patent/JP7392954B2/ja active Active
- 2018-09-18 AU AU2018333072A patent/AU2018333072B2/en active Active
- 2018-09-18 US US16/648,088 patent/US11471477B2/en active Active
- 2018-09-18 CA CA3075784A patent/CA3075784A1/en active Pending
- 2018-09-18 EP EP18856034.6A patent/EP3684420A4/en active Pending
- 2018-09-18 WO PCT/US2018/051489 patent/WO2019055977A1/en not_active Ceased
- 2018-09-18 CN CN201880060608.XA patent/CN111278469A/zh active Pending
-
2022
- 2022-08-29 US US17/823,028 patent/US20230285439A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534354A5 (enExample) | ||
| Fu et al. | Regulatory networks of LncRNA MALAT-1 in cancer | |
| Li et al. | Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer | |
| Liu et al. | miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway | |
| Yang et al. | MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway | |
| Al-Khalaf et al. | MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT | |
| Guo et al. | Lentivirus‐mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo | |
| Li et al. | Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma | |
| Avan et al. | Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer | |
| Kindt et al. | Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets | |
| Zhang et al. | CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer | |
| Chen et al. | The roles of miR-200c in colon cancer and associated molecular mechanisms | |
| Zarredar et al. | Critical microRNAs in lung cancer: recent advances and potential applications | |
| Geng et al. | MicroRNA-365a-3p promotes tumor growth and metastasis in laryngeal squamous cell carcinoma | |
| Pan et al. | MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2 | |
| Pai et al. | Prospects of miRNA-based therapy for pancreatic cancer | |
| Zhou et al. | MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1 | |
| Li et al. | Pituitary tumor-transforming gene 1 enhances metastases of cervical cancer cells through miR-3666-regulated ZEB1 | |
| Han et al. | Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming | |
| Shi et al. | SET8 expression is associated with overall survival in gastric cancer | |
| Zhu et al. | RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells | |
| Sun et al. | Antagomir-1290 suppresses CD133+ cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase | |
| Czerniak et al. | Biomarkers could facilitate prediction of worse clinical outcome of cancer with special insight to cervical cancer | |
| Zaczek et al. | Mechanisms of senescence in cancer: positive and negative aspects of cancer cells senescence | |
| Nasrolahi et al. | Long non-coding RNAs involved in retinoblastoma |